Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction (HEARTPOWER)
A Randomized Controlled Trial of the Efficacy and Safety of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Sponsor: SPH Qingdao Growful Pharmacetical Co.,Ltd
A PHASE4 clinical study on Cardiac Dysfunction and Coronary Heart Disease, this trial is actively recruiting participants. The trial is conducted by SPH Qingdao Growful Pharmacetical Co.,Ltd and has accumulated 2 data snapshots since 2025. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
2 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Sep 2025 — Dec 2025 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- SPH Qingdao Growful Pharmacetical Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baoding, China , Beijing, China , Cangzhou, China , Changchun, China , Changsha, China , Chengdu, China , Chifeng, China , Chongqing, China , Dalian, China , Dandong, China and 48 more locations